Tyrosine Kinase Inhibitors Market Size & Share - Industry Trends and Forecast 2017 - 2025

" Tyrosine Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025" is the latest addition to MarketResearchReports.Biz industry research reports collection.


The objectives of this study are as follows:

To define, describe, and forecast the "Tyrosine Kinase Inhibitors" market by type, application, component, delivery model, end user, and region
To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the market size of market segments with respect to the four key regions: North America, Europe, Asia, and the Rest of the World (RoW)
To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1825169

Tyrosine kinase is a subclass of protein kinases family of enzymes responsible for phosphorylation. These are directly involved in cell division. Hence, kinase inhibitors are used in cancer treatment to prevent unregulated cellular proliferation. Tyrosine kinase inhibitors (TKI) comes under targeted therapy. TKI can be taken orally as pills. Only specific cancer cells can be treated in targeted therapy while causing minimum damage to normal cells. In chronic myeloid leukemia (CML), tyrosine kinase inhibitors target the abnormal BCR-ABL (Abelson murine leukemia) protein that causes unregulated CML cell growth and stops its function which causes the death of CML cells.

The global tyrosine kinase inhibitors market can be segmented based on product type, treatment type, and end-user. In terms of product type, tyrosine kinase inhibitors market can be bifurcated into receptor tyrosine kinase inhibitors and non-receptor tyrosine kinase inhibitors. The receptor tyrosine kinase inhibitors family include epidermal growth factor receptor family (EFGR), insulin-like growth factor receptor (IGF-R), human epidermal growth factor receptor 2 (HER2), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR). Non-receptor tyrosine kinase inhibitors include BCR-ABL tyrosine-kinase inhibitors, mesenchymal-epithelial transition growth factor (c-MET), Janus kinase (JAK) Inhibitor, and spleen tyrosine kinase (SYK) inhibitors. Based on treatment type, the global tyrosine kinase inhibitors market can be classified into first-line treatment, second-line treatment, and third-line treatment. If first-line treatment does not work because of intolerance to a particular drug or drug resistance, then the second-line treatment is given. If both the initial treatment and subsequent treatment (second-line) fail to work, a third treatment option (third-line treatment) can be offered to patients. Three TKI drugs have been approved as initial therapy (first-line treatment) for chronic phase CML. These drugs are Imatinib mesylate (Gleevec), Nilotinib (Tasigna), and Dasatinib (Sprycel). In case of resistance to second-line treatments, other TKI options (third-line treatment) include drugs such as Bosutinib (Bosulif) and Ponatinib (Iclusig). In terms of end-user, the global tyrosine kinase inhibitors market can be divided into pharmaceutical companies, private & government research institutes, academic institutes, and health care facilities.

View Full Report @ https://www.marketresearchreports.biz/reports/1825169/tyrosine-kinase-inhibitors-global-market-research-reports

The global tyrosine kinase inhibitors market is growing at a rapid pace, with numerous products at various phases of industry lifecycle. Significant investments in research and development is attributed to the growth of tyrosine kinase inhibitors market. Moreover, increase in the incidence of chronic diseases such as cancer has attracted several pharmaceutical companies to invest in tyrosine kinase inhibitors market. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first to enter the global tyrosine kinase inhibitors market. Small molecule-based targeted therapeutics can give tough competition to widely accepted monoclonal antibodies in terms of pharmacological efficacy. However, pricing and commercialization strategies are also expected to play a major role. Risk factors associated with the usage of tyrosine kinase inhibitors and the ability to interact with other drugs are the major factors restraining tyrosine kinase inhibitors market. Patients with a history of peripheral vascular disease and cardiac disease need to be monitored carefully and frequently during TKI treatment. TKIs can have serious interactions with other prescription medications, over-the-counter medications, supplements, and even certain foods.

The global tyrosine kinase inhibitors market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to account for significant share of the global tyrosine kinase inhibitors market owing to rise in technological advancements in medical research and availability of high-tech health care infrastructure. Additionally, increase in number of clinical trials is projected to fuel the growth of the tyrosine kinase inhibitors market in these two regions. Presence of leading players in these regions is likely to augment tyrosine kinase inhibitors market in the next few years. Furthermore, rise in incidence of various types of cancers and increase in disposable income of consumers, especially in emerging nations such as China and India are expected to fuel the growth of the tyrosine kinase inhibitors market in Asia Pacific. High awareness about the availability of tyrosine kinase inhibitors and rise in adoption of advanced technologies in cancer treatment are the factors anticipated to propel the tyrosine kinase inhibitors market in Latin America and the Middle East.

Leading players operating in the global kinase inhibitors market are Roche, Novartis, AstraZeneca, Bayer, Pfizer, and GlaxoSmithKline.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Enquiry @ https://www.marketresearchreports.biz/sample/enquiry/1825169

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Us

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.